

FORM 7

MONTHLY PROGRESS REPORT – April 2015

Name of CNSX Issuer: Pivotal Therapeutics Inc. (the "Issuer").

Trading Symbol: PVO

Number of Outstanding Listed Securities: 94,232,988 common shares

Date: May 6, 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Over the previous month, the Issuer's business activities have been focused on continuing the commercialization of its lead products **VASCAZEN**[®], **OMAZEN**[®] and a new product **BeneFishial**[™]. **VASCAZEN**[®] is a prescription-only medical food for the dietary management of an Omega-3 deficiency in patients with cardiovascular disease. The product is readily available for sale through a prescription in all major pharmacies across the U.S. **OMAZEN**[®] is Pivotal's second product to market for the maintenance of good health, contains greater than 90% pure pharmaceutical grade Omega-3 with the optimal 6:1 ratio of EPA to DHA. **OMAZEN**[®] is available for sale and distribution in Canada only and is positioned for the professional OTC market. **BeneFishial**[™] is the first product in Pivotal's new nutraceutical product line, which has been specifically designed to be sold in the OTC direct to retail and/or direct to consumer markets.

April was a busy month for the Company with the announcement of a lot of positive news. On the first of the month, the Company received a Notice of Allowance for U.S. Patent Application Serial Number 13/584,428 entitled "Omega 3 Fatty Acid for use as a Prescription Medical Food and Omega 3 Fatty Acid Diagnostic Assay for the Dietary Management of Cardiovascular patients with Cardiovascular Disease (CVD) who are Deficient in Blood EPA and DHA Levels." The Company announced that Dr. Yannick Georg, POMECA trial chief investigator in France, was designated laureate of the EUR 30,000 young researcher French Interregional Clinical Research and Innovation (GIRCI Est) Award. Also, during the month the Company announced it entered into a Memorandum of Understanding with Korea Animal Medical Science Institute (KAMSI) and its newly created affiliate for the exclusive sales and distribution of the **BeneFishial**[™] family of products in Korea. The **BeneFishial**[™] family of products consists of the following six products: (i) **BeneFishial**[™] for overall health and well being, (ii) **BeneFishial**[™] for cardiovascular health, (iii) **BeneFishial**[™] for prenatal health, (iv) **BeneFishial**[™] for toddler's health, (v) **BeneFishial**[™] for child's health and (vi) **BeneFishial**[™] for pet's health (veterinary application). On April 27, 2015 the company received Health Canada approval to expand the indication of **OMAZEN**[®]'s product line specifically for cardiovascular health. The Natural and Non-Prescription Health Products Directorate of Health Canada (NNHPD) issued Natural Product Number (NPN) **NPN 80060196** with the claim that *helps to maintain and support cardiovascular health* and **NPN 80060197** with the claim *helps to support and maintain normal serum/blood triglycerides/triacylglycerol levels*. On April 30, 2015 the Company announced its 2014 financial results.

2. Provide a general overview and discussion of the activities of management.

Management is continuing to work and deliver on the objectives laid out in the business plan to grow sales of its products **VASCAZEN**[®], **OMAZEN**[®] and **Benefishial**[™] and to develop a rapid format point-of-care (POC) test to identify Omega-3 deficient patients to increase shareholder value. Additionally, management continues to build relationships in the business community in which it operates.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

This item is not applicable to the Issuer for the month of April 2015.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This item is not applicable to the Issuer for the month of April 2015.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of.

This item is not applicable to the Issuer for the month of April 2015.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

This item is not applicable to the Issuer for the month of April 2015.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if

applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

This item is not applicable to the Issuer for the month of April 2015.

8. Describe the acquisition of new customers or loss of customers.

This item is not applicable to the Issuer for the month of April 2015.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

During the month the Company received a Notice of Allowance for U.S. Patent Application Serial Number 13/584,428 entitled "Omega 3 Fatty Acid for use as a Prescription Medical Food and Omega 3 Fatty Acid Diagnostic Assay for the Dietary Management of Cardiovascular patients with Cardiovascular Disease (CVD) who are Deficient in Blood EPA and DHA Levels."

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This item is not applicable to the Issuer for the month of April 2015.

11. Report on any labour disputes and resolutions of those disputes if applicable.

This item is not applicable to the Issuer.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

This item is not applicable to the Issuer.

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

This item is not applicable to the Issuer for the month of April 2015.

- 14. Provide details of any securities issued and options or warrants granted.**

This item is not applicable to the Issuer for the month of April 2015.

- 15. Provide details of any loans to or by Related Persons.**

This item is not applicable to the Issuer for the month of April 2015.

- 16. Provide details of any changes in directors, officers or committee members.**

This item is not applicable to the Issuer for the month of April 2015.

- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1)
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2015

Rachelle MacSweeney
Name of Director or Senior
Officer

“Rachelle MacSweeney”
Signature

President, Chief Operating
Officer and Director
Official Capacity

<i>Issuer Details</i>	<u>For Month End</u>	<u>Date of Report</u>
<u>Name of Issuer</u> Pivotal Therapeutics Inc.	April 30, 2015	(YY/MM/D) 15/05/06
<u>Issuer Address</u> 81 Zenway Blvd., Unit 10		
<u>City/Province/Postal Code</u> Woodbridge, Ontario L4H 0S5	<u>Issuer Fax No.</u> (905) 856-2177	<u>Issuer Telephone No.</u> (905) 856-9797
<u>Contact Name</u> Rachelle MacSweeney	<u>Contact Position</u> President, Chief Operating Officer & Director	<u>Contact Telephone No.</u> (905) 856-9797
<u>Contact Email Address</u> rmacsweeney@pivotaltherapeutics.us	<u>Web Site Address</u> www.pivotaltherapeutics.us	

FORM 7 – MONTHLY PROGRESS REPORT

November 14, 2008

Page 7